$PTCT
PTC Therapeutics Inc Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000107008118000050 Filed on May 09, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$68.74M	$56.06M	$26.55M
YoY Change	43.33%	111.18%	40.5%
Cost Of Revenue	$2.572M	$3.045M	$39.00K
YoY Change	239.31%	7707.69%
Gross Profit	$66.17M	$53.02M	$26.51M
YoY Change	40.18%	100.0%	40.29%
Gross Profit Margin	96.26%	94.57%	99.85%
Selling, General & Admin	$33.55M	$32.97M	$25.50M
YoY Change	16.21%	29.29%	-1.69%
% of Gross Profit	50.69%	62.19%	96.2%
Research & Development	$32.61M	$31.36M	$27.36M
YoY Change	5.75%	14.62%	-12.85%
% of Gross Profit	49.28%	59.16%	103.23%
Depreciation & Amortization	$6.220M	$6.022M	$612.0K
YoY Change	640.48%	883.99%	-27.92%
% of Gross Profit	9.4%	11.36%	2.31%
Operating Expenses	$74.32M	$72.81M	$52.90M
YoY Change	22.92%	37.62%	-7.73%
Operating Profit	-$5.574M	-$16.74M	-$26.36M
YoY Change	-55.4%	-36.47%	-31.44%
Interest Expense	-$2.884M	-$3.303M	-$2.219M
YoY Change	-4.12%	48.85%	13.45%
% of Operating Profit
Other Income/Expense, Net	-$673.0K	$1.004M	-$318.0K
YoY Change	-63.02%	-415.72%	-55.89%
Pretax Income	-$9.131M	-$19.04M	-$28.89M
YoY Change	-47.3%	-34.09%	-29.74%
Income Tax	$389.0K	$221.0K	$165.0K
% Of Pretax Income
Net Earnings	-$9.520M	-$19.26M	-$29.06M
YoY Change	-45.52%	-33.71%	-29.53%
Net Earnings / Revenue	-13.85%	-34.36%	-109.45%
Basic Earnings Per Share
Diluted Earnings Per Share	-$206.1K	-$463.9K	-$848.4K
COMMON SHARES
Basic Shares Outstanding	46.45M shares	41.80M shares	34.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$296.1M	$178.3M	$202.6M
YoY Change	63.5%	-11.99%	-32.17%
Cash & Equivalents	$223.8M	$97.68M	$54.11M
Short-Term Investments	$72.30M	$80.60M	$148.5M
Other Short-Term Assets	$6.300M	$5.800M	$4.600M
YoY Change	21.15%	26.09%	-9.8%
Inventory	$13.85M	$12.36M	$1.354M
Prepaid Expenses
Receivables	$59.40M	$45.60M	$32.20M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$375.6M	$242.0M	$240.7M
YoY Change	65.5%	0.53%	-26.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.217M	$8.302M	$7.059M
YoY Change	20.15%	17.61%	-15.96%
Goodwill
YoY Change
Intangibles	$126.3M	$127.6M
YoY Change	-14.75%
Long-Term Investments
YoY Change
Other Assets	$1.600M	$1.500M	$900.0K
YoY Change	45.45%	66.67%	125.0%
Total Long-Term Assets	$136.1M	$137.4M	$7.918M
YoY Change	-12.8%	1635.48%	-10.02%
TOTAL ASSETS
Total Short-Term Assets	$375.6M	$242.0M	$240.7M
Total Long-Term Assets	$136.1M	$137.4M	$7.918M
Total Assets	$511.8M	$379.4M	$248.6M
YoY Change	33.59%	52.59%	-25.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.364M	$3.104M	$3.579M
YoY Change	-28.01%	-13.27%	-77.63%
Accrued Expenses	$13.00M	$9.200M	$7.600M
YoY Change	17.12%	21.05%	123.53%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.666M
YoY Change
Total Short-Term Liabilities	$86.47M	$72.72M	$45.42M
YoY Change	27.2%	60.1%	3.46%
LONG-TERM LIABILITIES
Long-Term Debt	$147.2M	$146.9M	$99.90M
YoY Change	4.22%	47.03%	6.95%
Other Long-Term Liabilities	$153.0K	$209.0K	$311.0K
YoY Change	-47.6%	-32.8%	-84.45%
Total Long-Term Liabilities	$147.4M	$147.1M	$100.2M
YoY Change	4.11%	46.78%	5.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$86.47M	$72.72M	$45.42M
Total Long-Term Liabilities	$147.4M	$147.1M	$100.2M
Total Liabilities	$244.4M	$229.1M	$147.8M
YoY Change	14.54%	54.99%	6.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$839.6M	-$830.1M	-$764.2M
YoY Change	7.42%	8.63%
Common Stock	$47.00K	$42.00K	$34.00K
YoY Change	14.63%	23.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$267.4M	$150.3M	$100.8M
YoY Change
Total Liabilities & Shareholders Equity	$511.8M	$379.4M	$248.6M
YoY Change	33.59%	52.59%	-25.82%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$9.520M	-$19.26M	-$29.06M
YoY Change	-45.52%	-33.71%	-29.53%
Depreciation, Depletion And Amortization	$6.220M	$6.022M	$612.0K
YoY Change	640.48%	883.99%	-27.92%
Cash From Operating Activities	$0.00	-$15.88M	-$28.90M
YoY Change	-100.0%	-45.06%	-30.51%
INVESTING ACTIVITIES
Capital Expenditures	-$710.0K	$479.0K	$225.0K
YoY Change	102.86%	112.89%	-15.09%
Acquisitions
YoY Change
Other Investing Activities	$8.450M	-$1.170M	$24.64M
YoY Change	-64.54%	-104.75%	10.1%
Cash From Investing Activities	$7.750M	-$1.648M	$24.42M
YoY Change	-66.98%	-106.75%	10.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$117.9M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	121.6M	$1.136M	$663.0K
YoY Change	204.08%	71.34%	2110.0%
NET CHANGE
Cash From Operating Activities	0.000	-$15.88M	-$28.90M
Cash From Investing Activities	7.750M	-$1.648M	$24.42M
Cash From Financing Activities	121.6M	$1.136M	$663.0K
Net Change In Cash	129.4M	-$16.39M	-$3.821M
YoY Change	68.49%	328.95%	-80.34%
FREE CASH FLOW
Cash From Operating Activities	$0.00	-$15.88M	-$28.90M
Capital Expenditures	-$710.0K	$479.0K	$225.0K
Free Cash Flow	$710.0K	-$16.36M	-$29.13M
YoY Change	-94.81%	-43.84%	-30.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46445672	shares
CY2018Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	PTC THERAPEUTICS, INC.
CY2017Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	5137000	USD
CY2018Q1	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	6570000	USD
CY2017Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	10077000	USD
CY2018Q1	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	0	USD
CY2017Q1	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	105000	USD
CY2018Q1	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	81000	USD
CY2018Q1	ptct	Contract With Customer Liability Amounts Recognized Beginning Of Measurement Period ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod	0	USD
CY2018Q1	ptct	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	1346000	USD
CY2017Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	1221000	USD
CY2018Q1	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	1548000	USD
CY2017Q4	ptct	Fair Value Assets Transfers Between Level1 And Level2 Amount FairValueAssetsTransfersBetweenLevel1AndLevel2Amount	0	USD
CY2018Q1	ptct	Fair Value Assets Transfers Between Level1 And Level2 Amount FairValueAssetsTransfersBetweenLevel1AndLevel2Amount	0	USD
CY2014Q3	ptct	Minimum Age Of Ambulatory Patient MinimumAgeOfAmbulatoryPatient	P5Y
CY2017Q1	ptct	Net Product Sales NetProductSales	26442000	USD
CY2018Q1	ptct	Net Product Sales NetProductSales	55981000	USD
CY2014Q3	ptct	Number Of States In European Economic Area NumberOfStatesInEuropeanEconomicArea	31	member_state
CY2017Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	22257000	USD
CY2018Q1	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	25098000	USD
CY2017Q4	ptct	Sales Rebates And Royalties Current SalesRebatesAndRoyaltiesCurrent	11657000	USD
CY2018Q1	ptct	Sales Rebates And Royalties Current SalesRebatesAndRoyaltiesCurrent	16380000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	76446000	USD
CY2018Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	71437000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15282000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3104000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-208000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	96000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2116000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3100000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3969000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4953000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	0	USD
CY2018Q1	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	-3937000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	55981000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	966534000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	975418000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9029000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7748000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	800000	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	800000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	80000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	126000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5428000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7573884	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8792152	shares
CY2017Q4	us-gaap	Assets Assets	391653000	USD
CY2018Q1	us-gaap	Assets Assets	379411000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	249063000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	241996000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	79454000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	80595000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	52000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	30000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	131000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	79432000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	80696000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	69377000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	80595000	USD
CY2017	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58321000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54106000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111792000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97675000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4215000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14117000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41612395	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41809398	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41612395	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41809398	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28448000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18279000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11891000	USD
CY2018Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	39000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3045000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3937000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	7954000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9300000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	612000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	6022000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-394000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2273000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17711000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9243000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	60000000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M17D
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-820000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1300000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28892000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19042000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	165000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	221000	USD
CY2017Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	28000	USD
CY2018Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	326000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3923000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6810000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	582000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1409000	USD
CY2017Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	226000	USD
CY2018Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	308000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1350000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1446000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-624000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-475000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-93000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-958000	USD
CY2017Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	6746000	USD
CY2018Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	4223000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	132993000	USD
CY2018Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	127565000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2219000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3303000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	2250000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	3023000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6390000	USD
CY2018Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6801000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	10754000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	12355000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	452000	USD
CY2018Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	768000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3912000	USD
CY2018Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4786000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	235216000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	229103000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391653000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	379411000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	82048000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	72716000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	144971000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	146878000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	79454000	USD
CY2018Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	80595000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	663000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1136000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24418000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1648000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28902000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15878000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-29057000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-19263000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29057000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19263000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	52902000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	72805000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26355000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16743000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2286000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7942000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-22000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-123000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	631000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1107000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	984000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	984000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1665000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1279000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	243000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	209000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-318000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1004000	USD
CY2017Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1600000	USD
CY2018Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1780000	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	19467000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22683000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	225000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	479000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6669000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5760000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	44110000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	21514000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	106000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1136000	USD
CY2017Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	557000	USD
CY2018Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8376000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8302000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	40394000	USD
CY2018Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	45611000	USD
CY2018Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27363000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31363000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-814108000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-830100000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-830105000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	26547000	USD
CY2018Q1	us-gaap	Sales Revenue Net SalesRevenueNet	56062000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25500000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32969000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9029000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7748000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	156437000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	150308000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34305948	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41626617	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company has launched two rare disease products and has a global commercial footprint. The Company’s recent ability to commercialize products is the foundation that drives its continued investment in a robust pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has two products, Translarna</font><font style="font-family:inherit;font-size:8pt;">™ </font><font style="font-family:inherit;font-size:10pt;">(ataluren) and Emflaza™ (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna received marketing authorization from the European Commission in August 2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years and older in the </font><font style="font-family:inherit;font-size:10pt;">31</font><font style="font-family:inherit;font-size:10pt;"> member states of the European Economic Area, or EEA. Emflaza is approved in the United States for the treatment of DMD in patients five years and older. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the European Medicines Agency, or EMA, of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna in the approved patient population. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2021. The Company refers to the trial and open-label extension together as Study 041.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The marketing authorization in the EEA was last renewed in June 2017 and is effective, unless extended, through August 5, 2018. In February 2018, the Company submitted a marketing authorization renewal request to the EMA. The renewal was based on the Company’s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company initiated reimbursed early access programs, or EAP programs, for Translarna for nmDMD patients in selected territories in the EEA and recorded its first sales of Translarna in the third quarter of 2014 pursuant to an EAP program. In December 2014, the Company recorded its first commercial sales in Germany. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, Translarna was available in over </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;"> countries on a commercial basis or pursuant to an EAP program. The Company expects to expand its launch activities across the EEA pursuant to the marketing authorization granted by the EMA throughout 2018 and future years, subject to continued renewal of its marketing authorization following annual EMA reassessments and successful completion of pricing and reimbursement negotiations. Concurrently, the Company plans to continue to pursue EAP programs in select countries where those mechanisms exist, both within the EEA and in other countries that will reference the marketing authorization in the EEA.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the United States Food and Drug Administration, (the "FDA"), for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied PTC’s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. The Company intends to follow the FDA’s recommendation and will collect such dystrophin data using newer technologies via procedures and methods that it is currently designing and expects to initiate such a study by the end of 2018. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The NDA, which seeks approval of Translarna for the treatment of nmDMD in the United States, was initially submitted by the Company in December 2015. In February 2016, following the submission, the Company received a Refuse to File letter from the FDA regarding the NDA. The FDA stated in the Refuse to File letter that the NDA was not sufficiently complete to permit a substantive review. Specifically, the Company was notified in the letter that, in the view of the FDA, both the Phase 2b and Phase 3 ACT DMD trials were negative and do not provide substantial evidence of effectiveness and that the NDA did not contain adequate information regarding the abuse potential of Translarna. Additionally, the FDA stated that the Company had proposed a post-hoc adjustment of ACT DMD that eliminates data from a majority of enrolled patients. During July 2016, the Company appealed the Refuse to File decision via the formal dispute resolution process within FDA’s Center for Drug Evaluation and Research; however, this appeal was denied by the FDA’s Office of Drug Evaluation I in October 2016. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 20, 2017, the Company completed its acquisition of all rights to Emflaza, or the Transaction. Emflaza is approved in the United States for the treatment of DMD in patients five years and older. The Transaction was completed pursuant to an asset purchase agreement, dated March 15, 2017, as amended on April 20, 2017, (the "Asset Purchase Agreement"), by and between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon. The Transaction was accounted for as an asset acquisition. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. The Company assumed certain liabilities and obligations in the Transaction arising out of, or relating to, the assets acquired in the Transaction. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the Transaction, the Company paid to Marathon total upfront consideration comprised of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, funded through cash on hand, and </font><font style="font-family:inherit;font-size:10pt;">6,683,598</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock. The number of shares of common stock issued at closing was determined by dividing </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;"> by the volume weighted average price per share of the Company’s common stock on the Nasdaq Stock Market for the </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> trading-day period ending on the third trading day immediately preceding the closing. Marathon will be entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset, and a single </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> sales-based milestone, in each case subject to the terms and conditions of the Asset Purchase Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$830.1 million</font><font style="font-family:inherit;font-size:10pt;">. The Company has financed its operations to date primarily through the private offering in August 2015 of </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2022 (see Note 9), public offerings of common stock in February 2014 and October 2014, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and in May 2017, the Company began to recognize revenue generated from net sales of Emflaza for the treatment of DMD in the United States. The Company expects that the cash flows from the sales of its products, together with the Company's cash, cash equivalents and marketable securities, including the net proceeds from the Company's underwritten public offering of its common stock that close in April 2018 as discussed in Note 12, will be sufficient to fund its operations for at least the next twelve months.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company’s research and development expenses, stock-based compensation, valuation procedures for the convertible notes, allowance for doubtful accounts, inventory, acquired intangible assets, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div>

Files In Submission

Name	View Source	Status
0001070081-18-000050-index-headers.html	Edgar Link	pending
0001070081-18-000050-index.html	Edgar Link	pending
0001070081-18-000050.txt	Edgar Link	pending
0001070081-18-000050-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ptct-20180331.xml	Edgar Link	completed
ptct-20180331.xsd	Edgar Link	pending
ptct-20180331_cal.xml	Edgar Link	unprocessable
ptct-20180331_def.xml	Edgar Link	unprocessable
ptct-20180331_lab.xml	Edgar Link	unprocessable
ptct-20180331_pre.xml	Edgar Link	unprocessable
ptct0331201810-q.htm	Edgar Link	pending
ptct03312018ex-311.htm	Edgar Link	pending
ptct03312018ex-312.htm	Edgar Link	pending
ptct03312018ex-321.htm	Edgar Link	pending
ptct03312018ex-322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC Therapeutics Inc Stock $ptct

2018 Q2 Form 10-Q Financial Statement

#000107008118000050 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC Therapeutics Inc Stock $ptct

2018 Q2 Form 10-Q Financial Statement

#000107008118000050 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC Therapeutics Inc Stock $ptct